Author/Authors :
Liu ، Su-Tong Shanghai University of Traditional Chinese Medicine , Zhang ، Su-Fang Shanghai University of Traditional Chinese Medicine , Su ، Kai-Qi Shanghai University of Traditional Chinese Medicine , Luo ، Ying-Bin Shanghai University of Traditional Chinese Medicine , Fang ، Zhi-Hong Shanghai University of Traditional Chinese Medicine , Fang ، Yuan Shanghai University of Traditional Chinese Medicine , Xu ، Jing Shanghai University of Traditional Chinese Medicine , Wu ، Jian-Chun Shanghai University of Traditional Chinese Medicine , Li ، Yan Shanghai Municipal Hospital of Traditional Chinese Medicine
Abstract :
Objective: Traditional Chinese medicine (TCM) has been extensively used as one of popular alternative therapies for several cancers. However, it remains unclear whether TCM treatment is associated with longer survival in lung cancer patients. In this study, we explored the effect of longterm TCM treatment on patients with different stages of lung cancer. Methods: All information of lung cancer patients with stage IⅢ disease from January 2007 to September 2015 was collected for this retrospective cohort study. Those who were treated with TCM after surgery were divided into TCM group and the others were into the nonTCM group (control group). All patients were regularly followed up by clinic appointment or phone, and all survival data were collected from databases after the last followup in October 2017. Results: A total of 575 patients were included in this study, with 299 patients in the TCM group and 276 in the control group. For all patients, 5year diseasefree survival (DFS) was 62.2% in TCM group and 42.1% in the control group, and 6year DFSs were 51.8% and 35.4%, respectively (HR=0.51, 95% CI:0.40 to 0.66, logrank P≤ 0.001). For patients with stage I, 5year DFSs were 83.7% (TCM group) and 57.5% (control group) and 6year DFSs were 73.7% and 51.9%, respectively (HR=0.30, 95% CI:0.18 to 0.50, logrank P≤ 0.001). For patients with stage Ⅱ in the TCM group and the control group, 5year DFSs were 59.4% and 17.6% and 6year DFSs were 44.7% and 17.6%, respectively (HR=0.31, 95% CI:0.19 to 0.52, logrank P≤ 0.001), and for patients with stage Ⅲ, 5year and 6year DFSs in the TCM group were 18.7% and 12.5% compared with 28.4% and 20.3% in the control group (HR=1.06, 95% CI:0.72 to 1.56, logrank P=0.76). Conclusions: This study demonstrated that longterm TCM treatment as an adjuvant therapy is able to improve the DFS of postoperative stage IⅢ lung cancer patients, especially in patients with stage I and Ⅱ disease. However, these observational findings need being validated by large sample randomized controlled trials.
Keywords :
Traditional Chinese medicine , Lung cancer , Diseasefree survival , Retrospective study , Cohort study
